WEBULL
News
HALO
67.70
-1.81%
-1.25
Weekly Report: what happened at HALO last week (1222-1226)?
Weekly Report · 1d ago
Skye Bioscience Signs Collaboration and License Agreement with Halozyme
Reuters · 12/23 21:05
Does Halozyme Still Offer Value After a 44.5% Surge and Strong DCF Upside?
Simply Wall St · 12/23 10:20
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)
NASDAQ · 12/23 08:53
Weekly Report: what happened at HALO last week (1215-1219)?
Weekly Report · 12/22 09:04
Why Halozyme Therapeutics (HALO) Is Up 8.3% After FDA Nod And Patent Win In Lung Cancer
Simply Wall St · 12/21 11:12
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
NASDAQ · 12/20 05:44
Halozyme Therapeutics Price Target Maintained With a $90.00/Share by HC Wainwright & Co.
Dow Jones · 12/19 12:17
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $90 Price Target
Benzinga · 12/19 12:07
Rybrevant FASPRO Approval and ENHANZE Royalties Reset Halozyme’s Long-Term Growth Outlook, Supporting a Buy Rating and $90 Target
TipRanks · 12/19 11:25
Argenx cut to Neutral at Baird after trial setback for Vyvgart
Seeking Alpha · 12/18 19:53
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
NASDAQ · 12/18 17:48
J&J wins FDA nod for Rybrevant injectable in lung cancer
Seeking Alpha · 12/18 12:46
Johnson and Johnson’s Rybrevant Faspro combination in NSCLC approved by FDA
TipRanks · 12/18 12:11
Halozyme Says FDA Approves Johnson & Johnson's Five-Minute Injection Version Of Lung Cancer Drug RYBREVANT
Benzinga · 12/18 12:07
FDA Approves RYBREVANT FASPRO Co-Formulated with Halozyme's ENHANZE for Advanced EGFR-Mutated NSCLC
Reuters · 12/18 12:01
U.S. FDA APPROVES RYBREVANT FASPRO™ (AMIVANTAMAB AND HYALURONIDASE-LPUJ) CO-FORMULATED WITH ENHANZE® FOR THE TREATMENT OF ADVANCED EGFR-MUTATED NON-SMALL CELL LUNG CANCER
Reuters · 12/18 12:00
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
PR Newswire · 12/18 12:00
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Barchart · 12/16 12:17
Halozyme Therapeutics (HALO): A Fresh Look at Valuation After Board Appointment of Dealmaker Jim Lang
Simply Wall St · 12/16 10:14
More
Webull provides a variety of real-time HALO stock news. You can receive the latest news about Halozyme Thrp through multiple platforms. This information may help you make smarter investment decisions.
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.